实用癌症杂志
實用癌癥雜誌
실용암증잡지
The Practical Journal of Cancer
2015年
8期
1166-1169
,共4页
吉西他滨%顺铂%非小细胞肺癌%联合化疗
吉西他濱%順鉑%非小細胞肺癌%聯閤化療
길서타빈%순박%비소세포폐암%연합화료
Gemcitabine%Cisplatin%Non-small cell lung cancer( NSCLC)%Combination chemotherapy
目的 探讨吉西他滨和顺铂联合化疗治疗晚期非小细胞肺癌( NSCLC)的效果. 方法 对70例NSCLC患者采用GP(吉西他滨+顺铂)方案进行动静脉全身化疗治疗. 给予患者在数字减影血管造影机( DSA)的引导下行支气管动脉灌注( BAI)化疗,结合静脉滴注化疗药物. 同时给予水化、护肝,5-HT3 受体抑制剂防治呕吐等对症处理. 治疗2个周期后对患者的近期疗效进行评估、对不同解剖分型和不同病理类型患者的疗效进行比较、记录不良反应的情况. 结果 70例NSCLC患者中CR 5例,PR 38例,SD 19例,PD 8 例,总有效率为61.4%. GP方案在治疗不同类型的晚期NSCLC时,总有效率分别为:中央型肺癌75.0%,周围型肺癌36.8%;肺磷癌69.7%,肺腺癌43.3%. 中央型肺癌和周围型肺癌患者的疗效差异有统计学意义(χ2 =3.524,P=0.046);肺磷癌和肺腺癌患者的疗效差异有统计学意义(χ2 =4.541,P=0.037). 有23%的患者有Ⅱ度以上的血液系统的不良反应,而消化系统的恶心呕吐也仅是Ⅰ~Ⅱ度,但发生胸痛的患者有46例,其中32 例是Ⅰ度,程度较轻. 结论 吉西他滨和顺铂动静脉联合化疗治疗晚期非小细胞肺癌( NSCLC)对中央型肺癌、肺鳞癌的效果较好,不良反应较少、较轻,值得在临床工作中合理应用.
目的 探討吉西他濱和順鉑聯閤化療治療晚期非小細胞肺癌( NSCLC)的效果. 方法 對70例NSCLC患者採用GP(吉西他濱+順鉑)方案進行動靜脈全身化療治療. 給予患者在數字減影血管造影機( DSA)的引導下行支氣管動脈灌註( BAI)化療,結閤靜脈滴註化療藥物. 同時給予水化、護肝,5-HT3 受體抑製劑防治嘔吐等對癥處理. 治療2箇週期後對患者的近期療效進行評估、對不同解剖分型和不同病理類型患者的療效進行比較、記錄不良反應的情況. 結果 70例NSCLC患者中CR 5例,PR 38例,SD 19例,PD 8 例,總有效率為61.4%. GP方案在治療不同類型的晚期NSCLC時,總有效率分彆為:中央型肺癌75.0%,週圍型肺癌36.8%;肺燐癌69.7%,肺腺癌43.3%. 中央型肺癌和週圍型肺癌患者的療效差異有統計學意義(χ2 =3.524,P=0.046);肺燐癌和肺腺癌患者的療效差異有統計學意義(χ2 =4.541,P=0.037). 有23%的患者有Ⅱ度以上的血液繫統的不良反應,而消化繫統的噁心嘔吐也僅是Ⅰ~Ⅱ度,但髮生胸痛的患者有46例,其中32 例是Ⅰ度,程度較輕. 結論 吉西他濱和順鉑動靜脈聯閤化療治療晚期非小細胞肺癌( NSCLC)對中央型肺癌、肺鱗癌的效果較好,不良反應較少、較輕,值得在臨床工作中閤理應用.
목적 탐토길서타빈화순박연합화료치료만기비소세포폐암( NSCLC)적효과. 방법 대70례NSCLC환자채용GP(길서타빈+순박)방안진행동정맥전신화료치료. 급여환자재수자감영혈관조영궤( DSA)적인도하행지기관동맥관주( BAI)화료,결합정맥적주화료약물. 동시급여수화、호간,5-HT3 수체억제제방치구토등대증처리. 치료2개주기후대환자적근기료효진행평고、대불동해부분형화불동병리류형환자적료효진행비교、기록불량반응적정황. 결과 70례NSCLC환자중CR 5례,PR 38례,SD 19례,PD 8 례,총유효솔위61.4%. GP방안재치료불동류형적만기NSCLC시,총유효솔분별위:중앙형폐암75.0%,주위형폐암36.8%;폐린암69.7%,폐선암43.3%. 중앙형폐암화주위형폐암환자적료효차이유통계학의의(χ2 =3.524,P=0.046);폐린암화폐선암환자적료효차이유통계학의의(χ2 =4.541,P=0.037). 유23%적환자유Ⅱ도이상적혈액계통적불량반응,이소화계통적악심구토야부시Ⅰ~Ⅱ도,단발생흉통적환자유46례,기중32 례시Ⅰ도,정도교경. 결론 길서타빈화순박동정맥연합화료치료만기비소세포폐암( NSCLC)대중앙형폐암、폐린암적효과교호,불량반응교소、교경,치득재림상공작중합리응용.
Objective To study the efficacy of gemcitabine and cisplatin combined with chemotherapy for advanced non-small cell lung cancer ( NSCLC) .Methods 70 patients with NSCLC were treated with GP ( gemcitabine plus cisplatin) .Patients were treated with digital subtraction angiography (DSA) to guide the treatment of bronchial arterial infusion (BAI) chemothera-py,combined with intravenous infusion of chemotherapeutic drugs.At the same time,the patients were given water,liver,5-HT3 re-ceptor inhⅠBitors in prevention of vomiting symptom.After 2 cycles of treatment,the short-term efficacy of the patients was evalu-ated,and the effects of different anatomical and pathological types were compared.Results Among 70 NSCLC patients,there had 5 cases of CR,38 PR,19 SD,8 PD,and the total effective rate was 61.4%.In the treatment of different types of advanced NSCLC by GP,the total effective rate of central type lung cancer was 75%,peripheral lung cancer was 36.8%,squamous cell carcinoma was 69.7%,lung adenocarcinoma was 43.3%.There had statistically significant difference in efficacy of central type lung cancer and peripheral lung cancer (χ2 =3.524,P=0.046).There had statistically significant difference in efficacy of squamous cell carcinoma and lung adenocarcinoma (χ2 =4.541,P=0.037).23%patients had aboveⅡdegree adverse reactions of blood sys-tem,and the digestive system of nausea and vomiting was onlyⅠ~Ⅱdegree,but there had 46 cases of chest pain,of which 32 cases was grade I and,to a lesser extent.Conclusion Gemcitabine and cisplatin combined with intravenous chemotherapy in the treatment of advanced NSCLC of central type lung cancer,and lung squamous cell carcinoma is effective,with less and lighter ad-verse reactions,it is worthy of clinical application.
